skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Choking risk among psychiatric inpatients

Letter

(1858) Views  (331) Full article downloads

Authors: Nagamine T

Published Date June 2011 Volume 2011:7(1) Pages 381 - 382
DOI: http://dx.doi.org/10.2147/NDT.S22419

Takahiko Nagamine
1Division of Psychiatric Internal Medicine, Seiwakai-Kitsunan Hospital, Suzenji, Japan

Choking is a life-threatening and not infrequent occurrence in psychiatric hospitals. There is, however, little information available about the risk factors or methods to prevent choking. We conducted a retrospective analysis of the 8 patients who had a cardiopulmonary arrest due to choking and received resuscitation at our hospital during the 6-year period from April 2005 to March 2011. The study involved 6 males and females, all of whom were patients with schizophrenia taking antipsychotics orally. They were aged from 56 to 79 (mean ± SD: 69.0 ± 7.5 years), with the duration of illness from 28 to 54 years (39.9 ± 7.9 years). In 6 of the 8 cases, choking was diagnosed immediately on the basis of the situation at the time of cardiopulmonary arrest. In the remaining 2 cases, cardiopulmonary arrest was initially unexplained, and choking was only diagnosed subsequently. Choking was caused by bread in all cases. Tracheal intubation was carried out in all cases and resulted in successful resuscitation, causing no subsequent change in functions compared with the prechoking condition. All 8 patients had been receiving multiple antipsychotics before the event (mean number of drugs used 2.5 ± 0.7), with a total dose level ranging from 600 to 1800 mg/day chlorpromazine equivalents (mean 1113 ± 341 mg/day). Seven of the 8 patients had mild to moderate involuntary movements, and 5 patients were diagnosed with antipsychotic-induced tardive dyskinesia. During the 5-year period before the choking event, 7 of the 8 patients had at least 1 treatment interruption, and some patients had up to 4 interruptions.




 

Other articles by Dr Mike Briley

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Antidepressant therapy with milnacipran and venlafaxine
Editorial Foreword - Milnacipran: recent findings in depression
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Milnacipran: a unique antidepressant?
Milnacipran: recent findings in depression
Noradrenergic symptom cluster in depression
Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
The importance of norepinephrine in depression
The increasing burden of depression
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran


Readers of this article also read:

Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
ABO and rhesus blood group distribution in Kurds
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?
A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine